The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! About 164,385 shares traded hands or 47.20% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 35.14% since April 14, 2016 and is uptrending. It has outperformed by 30.45% the S&P500.
The move comes after 9 months negative chart setup for the $106.18M company. It was reported on Nov, 16 by Barchart.com. We have $2.50 PT which if reached, will make NASDAQ:FATE worth $12.74 million less.
Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage
Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. Wedbush maintained the shares of FATE in a report on Tuesday, November 8 with “Outperform” rating. TH Capital initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Thursday, September 22. TH Capital has “Buy” rating and $8 price target. The firm has “Buy” rating given on Thursday, September 22 by Roth Capital. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. Raymond James initiated it with “Outperform” rating and $8 target price in Tuesday, October 6 report. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets.
According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment decreased to 0.56 in Q2 2016. Its down 0.40, from 0.96 in 2016Q1. The ratio fall, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.
Tfs Capital accumulated 20,925 shares or 0.01% of the stock. Walleye Trading Ltd Limited Liability Company holds 0% or 1,100 shares in its portfolio. Polaris Venture Mgmt V accumulated 2.47 million shares or 4.51% of the stock. Lombard Odier Asset Management (Usa) has 0.05% invested in the company for 256,426 shares. Renaissance Techs Llc has 180,700 shares for 0% of their US portfolio. Goldman Sachs holds 35,966 shares or 0% of its portfolio. Blackrock Advsr Limited reported 4,030 shares or 0% of all its holdings. Blackrock Mngmt Ltd Llc last reported 0% of its portfolio in the stock. Jacobs Levy Equity Inc has 0.01% invested in the company for 178,647 shares. Bancshares Of Montreal Can, a Ontario – Canada-based fund reported 285 shares. Geode Cap Ltd, a Massachusetts-based fund reported 108,029 shares. Manufacturers Life Ins The last reported 184 shares in the company. Vanguard Group reported 657,573 shares or 0% of all its holdings. Blackrock Institutional Communication Na holds 0% or 5,728 shares in its portfolio. Board Of Trustees Of The Leland Stanford Junior University has 0.07% invested in the company for 291,067 shares.
More recent Fate Therapeutics Inc (NASDAQ:FATE) news were published by: 247Wallst.com which released: “Could This Be a Turning Point for Fate Therapeutics?” on June 20, 2016. Also Globenewswire.com published the news titled: “Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch …” on September 07, 2016. Globenewswire.com‘s news article titled: “Fate Therapeutics to Present at Biotech Showcase 2016” with publication date: January 06, 2016 was also an interesting one.
FATE Company Profile
Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.